4.6 Letter

Idelalisib in relapsed/refractory diffuse large B-cell lymphoma: results from a Nordic Lymphoma Group phase II trial

相关参考文献

注意:仅列出部分参考文献,下载原文获取全部文献信息。
Letter Hematology

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome

Andrea Visentin et al.

BRITISH JOURNAL OF HAEMATOLOGY (2019)

Article Biotechnology & Applied Microbiology

Rapid and complete response to idelalisib in a case of Richter syndrome

Cristina Bagacean et al.

ONCOTARGETS AND THERAPY (2019)

Review Oncology

The Role of PI3K Inhibition in Lymphoid Malignancies

Gottfried von Keudell et al.

CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2019)

Article Medicine, General & Internal

Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma

R. Schmitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Article Biochemistry & Molecular Biology

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

Wyndham H. Wilson et al.

NATURE MEDICINE (2015)

Article Hematology

The Genetic Landscape of Diffuse Large B-Cell Lymphoma

Laura Pasqualucci et al.

SEMINARS IN HEMATOLOGY (2015)

Article Multidisciplinary Sciences

Discovery and saturation analysis of cancer genes across 21 tumour types

Michael S. Lawrence et al.

NATURE (2014)

Article Multidisciplinary Sciences

PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma

Matthias Pfeifer et al.

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)